Eckert & Ziegler Strahlen- und Medizintechnik AG
Eckert & Ziegler Strahlen- und Medizintechnik AG Fundamental Analysis
Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ.DE) shows strong financial fundamentals with a PE ratio of 19.52, profit margin of 15.63%, and ROE of 20.78%. The company generates $0.3B in annual revenue with strong year-over-year growth of 20.22%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 80.8/100 based on profitability, valuation, growth, and balance sheet metrics. The B+ grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze EUZ.DE's fundamental strength across five key dimensions:
Efficiency Score
ExcellentEUZ.DE demonstrates superior asset utilization.
Valuation Score
ExcellentEUZ.DE trades at attractive valuation levels.
Growth Score
ExcellentEUZ.DE delivers strong and consistent growth momentum.
Financial Health Score
ExcellentEUZ.DE maintains a strong and stable balance sheet.
Profitability Score
ExcellentEUZ.DE achieves industry-leading margins.
Key Financial Metrics
Is EUZ.DE Expensive or Cheap?
P/E Ratio
EUZ.DE trades at 19.52 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, EUZ.DE's PEG of 0.75 indicates potential undervaluation.
Price to Book
The market values Eckert & Ziegler Strahlen- und Medizintechnik AG at 3.78 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 11.15 times EBITDA. This signals the market has high growth expectations.
How Well Does EUZ.DE Make Money?
Net Profit Margin
For every $100 in sales, Eckert & Ziegler Strahlen- und Medizintechnik AG keeps $15.63 as profit after all expenses.
Operating Margin
Core operations generate 24.06 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $20.78 in profit for every $100 of shareholder equity.
ROA
Eckert & Ziegler Strahlen- und Medizintechnik AG generates $10.04 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Eckert & Ziegler Strahlen- und Medizintechnik AG produces operating cash flow of $60.53M, showing steady but balanced cash generation.
Free Cash Flow
Eckert & Ziegler Strahlen- und Medizintechnik AG generates strong free cash flow of $34.46M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $0.55 in free cash annually.
FCF Yield
EUZ.DE converts 3.61% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
19.52
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.75
vs 25 benchmark
P/B Ratio
Price to book value ratio
3.78
vs 25 benchmark
P/S Ratio
Price to sales ratio
3.06
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.18
vs 25 benchmark
Current Ratio
Current assets to current liabilities
3.45
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.21
vs 25 benchmark
ROA
Return on assets percentage
0.10
vs 25 benchmark
ROCE
Return on capital employed
0.18
vs 25 benchmark
How EUZ.DE Stacks Against Its Sector Peers
| Metric | EUZ.DE Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 19.52 | 29.88 | Better (Cheaper) |
| ROE | 20.78% | 682.00% | Weak |
| Net Margin | 15.63% | -46037.00% (disorted) | Strong |
| Debt/Equity | 0.18 | 0.42 | Strong (Low Leverage) |
| Current Ratio | 3.45 | 4.49 | Strong Liquidity |
| ROA | 10.04% | -16420.00% (disorted) | Strong |
EUZ.DE outperforms its industry in 5 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Eckert & Ziegler Strahlen- und Medizintechnik AG's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
63.26%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
48.85%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
62.19%
Industry Style: Defensive, Growth, Innovation
High Growth